CUSIP: 74373B109
Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
11,016,657
-
Share change
-
-288,747
-
Total reported value
-
$12,563,413
-
Put/Call ratio
-
213%
-
Price per share
-
$1.14
-
Number of holders
-
41
-
Value change
-
-$1,124,687
-
Number of buys
-
18
-
Number of sells
-
22
Quarterly Holders Quick Answers
What is CUSIP 74373B109?
CUSIP 74373B109 identifies PTI - PROTEOSTASIS THERAPEUTICS IN - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2020
-
Previous quarter:
Q4 2019
Recent filing periods for CUSIP 74373B109:
Institutional Holders of PROTEOSTASIS THERAPEUTICS IN - COM (PTI) as of Q1 2020
As of 31 Mar 2020,
PROTEOSTASIS THERAPEUTICS IN - COM (PTI) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,016,657 shares.
The largest 10 holders included
SPHERA FUNDS MANAGEMENT LTD., VANGUARD GROUP INC, BlackRock Inc., Bain Capital Public Equity Management II, LLC, MACQUARIE GROUP LTD, WINTON GROUP Ltd, HarbourVest Partners LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, ACADIAN ASSET MANAGEMENT LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
41
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.